Levamlodipine-d4
Based on 1 Customer Validation
Levamlodipine-d4 is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis.
For research use only. We do not sell to patients.
- Purity: 99.74%
- CAS No.: 1346617-19-3
- Formula: C20H21D4ClN2O5
- Molecular Weight:412.90
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
All Calcium Channel Isoforms
More
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1346617-19-3
-
Unlabeled Cas 103129-82-4
-
Appearance Solid
-
Molecular Weight 412.90
-
Formula C20H21D4ClN2O5
-
Color White to off-white
-
SMILES
CCOC(C1=C(COC([2H])([2H])C([2H])([2H])N)NC(C)=C(C(OC)=O)[C@]1([H])C2=C(C=CC=C2)Cl)=O
-
Synonyms
(S)-Amlodipine-d4; Levoamlodipine-d4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
DMSO : 100 mg/mL (242.19 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[3]. Yang YL, et al. Synergic effects of levamlodipine and bisoprolol on blood pressure reduction and organ protection in spontaneously hypertensive rats. CNS Neurosci Ther. 2012;18(6):471-474. [Content Brief]
[4]. Wu J, et al. Development of levamlodipine long-acting patches based on an ion-pair strategy: Investigation of the mechanism for reducing skin irritation. Int J Pharm. 2024;665:124703. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4219 mL | 12.1095 mL | 24.2189 mL | 60.5473 mL |
| 5 mM | 0.4844 mL | 2.4219 mL | 4.8438 mL | 12.1095 mL | |
| 10 mM | 0.2422 mL | 1.2109 mL | 2.4219 mL | 6.0547 mL | |
| 15 mM | 0.1615 mL | 0.8073 mL | 1.6146 mL | 4.0365 mL | |
| 20 mM | 0.1211 mL | 0.6055 mL | 1.2109 mL | 3.0274 mL | |
| 25 mM | 0.0969 mL | 0.4844 mL | 0.9688 mL | 2.4219 mL | |
| 30 mM | 0.0807 mL | 0.4036 mL | 0.8073 mL | 2.0182 mL | |
| 40 mM | 0.0605 mL | 0.3027 mL | 0.6055 mL | 1.5137 mL | |
| 50 mM | 0.0484 mL | 0.2422 mL | 0.4844 mL | 1.2109 mL | |
| 60 mM | 0.0404 mL | 0.2018 mL | 0.4036 mL | 1.0091 mL | |
| 80 mM | 0.0303 mL | 0.1514 mL | 0.3027 mL | 0.7568 mL | |
| 100 mM | 0.0242 mL | 0.1211 mL | 0.2422 mL | 0.6055 mL |